CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Black Diamond Reports Updated Phase 2 Silevertinib Data, FDA Registration Path

By Reuters News

Nov 10 (Reuters) - Black Diamond Therapeutics Inc BDTX.O:

  • BLACK DIAMOND THERAPEUTICS ANNOUNCES POSITIVE UPDATED SILEVERTINIB PHASE 2 RESULTS, FDA FEEDBACK SUPPORTING A CLEAR PATH TO POTENTIAL REGISTRATION IN 1L EGFR-NCM NSCLC, AND PROVIDES CORPORATE UPDATE

  • BLACK DIAMOND THERAPEUTICS - 60% ORR, 93% DCR, 15.0 MONTH MPFS IN ITT POPULATION

  • BLACK DIAMOND THERAPEUTICS - 86% CNS-ORR, 12.2 MONTH SYSTEMIC MPFS IN UNTREATED BRAIN METASTASES

  • BLACK DIAMOND THERAPEUTICS INC: ASSUMING A Q2 OF 2027 INITIATION, PRELIMINARY DATA ANTICIPATED IN 2028 FOR PHASE 3 TRIAL

Further company coverage: BDTX.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.